pazopanib hydrochloride

Product Name: pazopanib hydrochloride
CAS:635702-64-6
MF:C21H23N7O2S.ClH
MW:473.987
EINECS:619-728-0
Product Categories:HFC80011
Mol File:635702-64-6.mol
PSA:127.41000
LogP:5.79510
Boiling Point:728.8ºC at 760 mmHg
Flash Point:394.6ºC
Place of Origin:China
Type:Antineoplastic Agents
Grade Standard:Medicine Grade
Purity:99%min
Appearance:white to off-White powder
COA:avaliable
Heavy Metals:NMT 20ppm
Loss on drying:NMT 1.0%
Shelf life:2 Years
Unspecified impurity:0.5%
Grade:Phamaceutical Grade
Packaging Details:Bulk qty: 25kg/drum, inside two level plastic bags
Small qty: Aluminium bag, inside two level plastic bags
Others: can do your package or split small packages according to your request
Description:The growth of solid tumors is dependent on angiogenesis, the process wherein new capillaries are formed from existing blood vessels. VEGF is one of the most important inducers of angiogenesis and expressed at high levels by most tumors. Hence, the inhibition of VEGF or its receptor signaling system is an attractive target for cancer therapeutics. The most studied and developed inhibitors are monoclonal antibodies that neutralize VEGF (e.g., bevacizumab), anti-VEGF ribozymes (e.g., angiozyme), and small-molecule VEGFR kinase inhibitors (e.g., sunitinib, sorafenib). Pazopanib is the latest VEGFR kinase inhibitor to reach the market. It is indicated for the oral treatment of advanced RCC. The biological functions of the VEGF family are mediated by activation of three structurally homologous tyrosine kinase receptors, VEGFR-1, VEGFR-2, and VEGFR3. In vitro, pazopanib inhibits VEGFR-1, VEGFR-2, and VEGFR-3 with IC50 values of 10, 30, and 47 nM, respectively. In addition, it inhibits several of the closely related tyrosine receptor kinases, including platelet-derived growth-factor receptor β(PDGFR-β), c-kit, and fibroblast growth factor receptor-1 (FGFR1) with IC50 values of 84, 74, and 140 nM, respectively. In human umbilical vein endothelial cells (HUVEC), pazopanib inhibits VEGF-induced proliferation more potently than basic fibroblast growth factor (bFGF)-stimulated proliferation (IC50 = 21 nM vs. 721 nM) and concentration-dependently inhibits VEGF-induced VEGFR-2 phosphorylation (IC50 = 7 nM). It also potently inhibits angiogenesis in Matrigel plug and corneal micropocket assays.
The most common adverse events associated with pazopanib were diarrhea, hypertension, hair depigmentation, nausea, anorexia, and vomiting.
Uses:Pazopanib Hydrochloride (GW786034, Votrient, Armala) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM, respectively.
Payment:WU, Wire Transfer/Telegraphic Transfer, Venmo,USA BANK ACCOUNT
Shipping:by TNT,FEDEX,DHL UPS,EMS etc
Shipping:
By Courier: Fedex, EMS, DHL, TNT, UPS, etc. 7-10 days product will reach you after payment received,  if it’s agreed as ready stock before order.
By air, airport to airport
By sea